Anaphylatoxins such as C3a and C5a are key players in the innate immune response, known for their potent pro-inflammatory activity. These small, cationic peptides are produced through the enzymatic cleavage of complement components C3, C4, and C5, with C3a and C5a binding to specific G-protein coupled receptors (GPCRs): C3aR (C3a receptor) and C5aR1/C5aR2 respectively.

While the pathological implications of the complement system are vast—ranging from cancer to autoimmune and inflammatory diseases—recent advances in immunological tools have made it possible to selectively study and modulate complement pathways using monoclonal antibodies against C3aR, particularly in research contexts.

This article explores the biology of C3aR, its role in disease, and the promise of research use only monoclonal antibodies targeting C3aR to unravel its therapeutic potential.

Complement component 3a receptor 1 (C3aR1) is a member of the rhodopsin-like GPCR family, recognized for transducing signals upon C3a binding. The human C3aR is a 482-amino-acid transmembrane protein with a notably large extracellular loop—crucial for high-affinity C3a binding. Upon ligand engagement, C3aR activation triggers calcium flux and downstream immune signaling pathways.

C3aR is highly expressed across immune and non-immune tissues, including:

• Granulocytes (eosinophils, basophils)

• Monocytes/macrophages

• CD4+ T lymphocytes

• Spleen, appendix, adipose tissue, spinal cord, lung, placenta

This broad expression underlines its importance in both innate and adaptive immune regulation.

As the complement system gains attention in drug discovery, monoclonal antibodies targeting C3aR (C3aR1) have become vital tools for preclinical research, receptor mapping, and pathway validation.

• High specificity: Antibodies can selectively bind C3aR without off-target effects seen in small-molecule inhibitors like SB-290157.

• Functional analysis: Blocking antibodies can dissect the role of C3aR in immune modulation, tumor infiltration, and cytokine signaling.

• Research use only (RUO): These antibodies are not intended for therapeutic use but are indispensable in laboratory models for immunology, oncology, and inflammation studies.

• Cancer Immunology: Blocking C3aR enhances anti-tumor responses by improving NK and CD8+ T cell activity.

• Autoimmune Disease Models: Study the role of C3aR in diseases like lupus, psoriasis, or rheumatoid arthritis.

• GPCR Functional Studies: Analyze signal transduction and receptor internalization in response to C3a stimulation.

C3aR’s involvement in disease is multifaceted. As a modulator of immune cell recruitment and cytokine production, C3aR plays a key role in both acute inflammation and chronic pathological conditions.

Recent studies suggest C3aR is upregulated in tumor-infiltrating CD8+ T cells (TILs), potentially functioning as a novel immune checkpoint. Targeting the C3a-C3aR axis has been shown to:

• Enhance T cell-mediated tumor suppression

• Improve NK cell migration into tumors

• Synergize with anti-PD-1 immunotherapies in preclinical models

However, widely used small molecules like SB-290157, while acting as a C3aR antagonist, also exhibit agonist effects on C5aR, complicating data interpretation. This underscores the need for highly specific monoclonal antibodies against C3aR for reliable research outcomes.

Despite promising insights, therapeutic development of anti-C3aR agents remains limited. Most current monoclonal antibodies are designated for research use only (RUO). Yet, these tools are crucial in:

• Uncovering new immunotherapeutic strategies

• Defining receptor-ligand interactions with high precision

• Avoiding cross-reactivity and functional ambiguity in GPCR signaling studies

As studies expand, monoclonal antibodies against C3aR will remain at the forefront of complement system research, offering high-fidelity tools for functional analysis, preclinical evaluation, and potentially future therapeutic development.

SYnAbs’ monoclonal antibodies against C3aR represent powerful instruments for studying the complex biology of the complement system. Their specificity, reliability, and suitability for a wide array of immunological assays make them indispensable for researchers seeking to:

• Characterize C3aR signaling in human disease models

• Explore complement-targeted immunotherapy

• Advance our understanding of GPCR roles in inflammation and cancer

As demand for C3aR-targeting research tools continues to rise, SYnAbs supports scientific innovation by delivering high-quality RUO monoclonal antibodies to accelerate discovery.

(1) Portier P, Richet C. De l'action anaphylactique de certains venins. C R Séances Soc Biol. 1902; 54: 170

(2) Friedberger E. Weitere Untersuchungen uber Eiweissanaphylaxie. Z Immunforsch Exp Ther 1910;4:636–89

(3)Lienenklaus S,Ames RS, Tornetta MA, Sarau HM, Foley JJ, Crass T, Sohns B, Raffetseder U, Grove M, Hölzer A, et al. (1998) Human anaphylatoxin C4a is a potent agonist of the guinea pig but not the human C3a receptor. J Immunol 161:2089–2093.

(4) Ames RS, Li Y, Sarau HM, Nuthulaganti P, Foley JJ, Ellis C, et al. Molecular cloning and characterization of the human anaphylatoxin C3a receptor. J Biol Chem 1996;271:20,231–4

(5) Crass T, Raffetseder U, Martin U, Grove M, Klos A, Kohl J, et al. Expression cloning of the human C3a anaphylatoxin receptor (C3aR) from differentiated U-937 cells. Eur J Immunol 1996;26:1944–50

(6) Boulay F, Mery L, Tardif M, Brouchon L, Vignais P. Expression cloning of a receptor for C5a anaphylatoxin on differentiated HL-60 cells. Biochemistry 1991;30:2993–9.

(7) Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J Biol Chem 2002;277:7165–9.

(8) Kupp LI, Kosco MH, Schenkein HA, Tew JG. Chemotaxis of germinal center B cells in response to C5a. Eur J Immunol 1991;21:2697–701.

(9) Markiewski MM, DeAngelis RA, Benencia F, et al. Modulation of the antitumor immune response by complement. Nat Immunol. 2008;9(11):1225-1235. doi:10.1038/ni.1655

(10) Wang Y, Sun SN, Liu Q, Yu YY, Guo J, Wang K, et al. Autocrine complement inhibits IL10-dependent T-cell-mediated antitumor immunity to promote tumor progression. Cancer Discov. (2016) 6:1–11. doi: 10.1158/2159-8290.CD-15-1412 


(11) Magrini E, Di Marco S, Mapelli SN, Perucchini C, Pasqualini F, Donato A, Guevara Lopez ML, Carriero R, Ponzetta A, Colombo P, Cananzi F, Supino D, Reis ES, Peano C, Inforzato A, Jaillon S, Doni A, Lambris JD, Mantovani A, Garlanda C. Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression. Nat Cancer. 2021 Feb;2(2):218-232. doi: 10.1038/s43018-021-00173-0. Epub 2021 Feb 18. PMID: 34505065; PMCID: PMC8425276.

(12) Li XX, Kumar V, Clark RJ, Lee JD, Woodruff TM. The "C3aR Antagonist" SB290157 is a Partial C5aR2 Agonist. Front Pharmacol. 2021 Jan 21;11:591398. doi: 10.3389/fphar.2020.591398. PMID: 33551801; PMCID: PMC7859635.

(13) Krieg C, Carloni S, Weber L, Fosso B, Hardiman G, Mileti E. Loss of C3aR induces immune infiltration and inflammatory microbiota in a new spontaneous model of colon cancer (2021). doi: https://doi.org/10.1101/2021.01.18.426963

(14) Nandagopal S, Li CG, Xu Y, Sodji QH, Graves EE, Giaccia AJ. C3aR Signaling Inhibits NK-cell Infiltration into the Tumor Microenvironment in Mouse Models. Cancer Immunol Res. 2022 Feb;10(2):245-258. doi: 10.1158/2326-6066.CIR-21-0435. Epub 2021 Nov 24. PMID: 34819308; PMCID: PMC9351714.

(15) Quaovi H. Sodji, Dhanya K. Nambiar, Vignesh Viswanathan, Rie von Eyben, Deana Colburg, Michael S. Binkley, Caiyun G. Li, Monica M. Olcina, Daniel T. Chang, Quynh-Thu Le, Amato J. Giaccia; The Combination of Radiotherapy and Complement C3a Inhibition Potentiates Natural Killer cell Functions Against Pancreatic Cancer. Cancer Research Communications 1 July 2022; 2 (7): 725–738. https://doi.org/10.1158/2767-9764.CRC-22-0069